What's Happening?
Novo Nordisk has partnered with Andel, a direct-to-employer marketplace, to provide a new pathway for employees to access semaglutide (Wegovy) for obesity treatment outside of traditional insurance plans. This collaboration addresses the increasing trend
of employers scaling back coverage for GLP-1 receptor agonists. The arrangement covers both injectable semaglutide, including the higher-dose semaglutide HD, and the once-daily semaglutide pill. Employers can choose their contribution level, which reduces employees' out-of-pocket costs while allowing companies to control their total spending. Andel manages the entire process through its app, from prescription verification to delivery. This initiative comes as a WTW survey indicates that only 53% of employers with over 100 workers now cover GLP-1s for weight loss, a decrease from 57% in 2025, with another 16% considering removing coverage.
Why It's Important?
This partnership offers a significant workaround for employees facing reduced or eliminated insurance coverage for GLP-1 medications, which are increasingly seen as crucial for obesity management. By allowing employers to directly subsidize these treatments, it provides a flexible solution that balances employee health needs with employer cost control. The rising cost of GLP-1s has been a major factor in employers pulling back coverage, with projections indicating an 8.2% increase in employer health benefit costs for 2027, partly driven by GLP-1 use. This new model could help maintain access to these drugs for a broader segment of the workforce, potentially improving public health outcomes related to obesity while offering employers a more predictable expense model compared to traditional insurance plans. It also highlights a growing trend of moving certain healthcare benefits outside conventional pharmacy benefit managers.
What's Next?
As more employers evaluate their healthcare benefits for 2027, this new collaboration between Novo Nordisk and Andel is likely to gain traction as an alternative solution for GLP-1 coverage. The model allows employers to offer support for semaglutide treatment without fully integrating it into their existing insurance plans, providing a middle ground between full coverage and no coverage. This could lead to more companies adopting similar direct-to-employer programs for high-cost medications. The success of this initiative may also influence other pharmaceutical companies to explore similar partnerships, further fragmenting the traditional healthcare benefits landscape. Employees will need to understand how their specific employer's contribution affects their out-of-pocket costs and how to utilize the Andel platform for prescription fulfillment.
Beyond the Headlines
This development signifies a broader shift in how high-cost specialty medications are financed and delivered in the U.S. healthcare system. As pharmaceutical costs continue to rise, employers are seeking innovative ways to manage expenses while still providing valuable benefits to their employees. This direct-to-employer model bypasses some complexities and costs associated with traditional insurance and pharmacy benefit managers, potentially creating a more streamlined and cost-effective pathway for certain treatments. However, it also raises questions about equity of access, as coverage will depend on individual employer decisions, potentially creating disparities among workers. The move could also signal a trend towards more personalized and direct healthcare purchasing models, challenging the established roles of insurers and PBMs in the benefits ecosystem.
